Vertex Positive Interim Results for Phase 3 of Povetacicept in IgA Nephropathy

 - For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<0.0001) –

- For the first secondary endpoint, povetacicept treatment led to a 77.4% reduction from baseline in serum Gd-IgA1, resulting in a statistically significant and clinically meaningful reduction of 79.3% (P<0.0001) versus placebo; for the second secondary endpoint, 85.1% of povetacicept-treated patients achieved hematuria resolution, resulting in a statistically significant and clinically meaningful improvement of 61.7% (P<0.0001) versus placebo –

- Povetacicept was generally safe and well tolerated –

- Vertex to complete Biologics License Application by the end of March for potential U.S. Accelerated Approval –

https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results